ValuentumAd

Official PayPal Seal














Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Apr 17, 2017
Which Mid-Stage Biotech Can Grow Into the Next Large Cap Biotech Behemoth?
Image Source: Steven Depolo. The biotech field is on the cutting edge of scientific research. The production of new therapies often positively affects the share price of these innovative companies as long-term revenue and earnings expectations become embedded in the stock price. Let’s take a look at several mid-stage biotechs that may grow into dominant players.
Feb 18, 2017
Johnson & Johnson's Oncology Division A Force to Be Reckoned With
Image Source: Open Grid Scheduler. Healthcare and consumer staples giant Johnson & Johnson is a core holding in both newsletter portfolios. Let’s take a deep dive into one of its key sources of growth, its ‘Pharmaceutical’ segment.
Jan 23, 2017
Have Bristol-Myers Squibb’s Shares Finally Found Support?
Image Source: kennijima. Bristol-Myers Squibb has seen its shares fall to $50 from nearly $80 in just the past few months as clinical outcomes of its crucial product Opdivo have come under fire. Have shares finally found support? Let’s have a look.
Jan 23, 2017
Novartis’ Continuous Dividend Growth and Promising Pipeline
Image Shown: Novartis’ dividend history, source: Novartis. Novartis may be in the penalty box, but a healthy dividend growth track record and a promising pipeline may be difficult to overlook. Let’s dig in.
Jan 19, 2017
The Dreaded Patent Cliff: 3 Pharmaceutical Companies at Risk
Image Source: Global Panorama. Let's have a look at 3 pharmaceutical giants that may encounter some troubles in coming years.
Dec 19, 2016
Dividend Increases/Decreases for the Week Ending December 16
Let's take a look at companies raising/lowering their dividends this week.
Nov 16, 2016
Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins.
Sep 24, 2016
Update on Teva and the Generics Market
Image Source: Teva. Best Ideas Newsletter portfolio holding has completed a major acquisition, further strengthening its position in the global generics market, and it expects the generics market to continue expanding at a solid rate.
Aug 10, 2016
Oncology News a Key Driver of Big Pharma
Image Source: Images Money. Oncology product portfolios and pipelines have been key factors in the big pharma industry as of late.
Jun 10, 2016
Stay In Tune with Our *NEW* Dividend Analysis
Let's showcase the incremental dividend analysis content that our team has been adding to the dividend reports. Let's examine constituents in the Machinery & Tools industry.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.